Navigation Links
Groundbreaking Consensus Statement Provides a Road Map for Treating Melanoma Patients with Cancer Immunotherapy
Date:8/27/2013

Milwaukee, WI (PRWEB) August 27, 2013

The first evidence-based consensus statement on tumor immunotherapy for the treatment of patients with melanoma has been released by the Society for Immunotherapy of Cancer (SITC) and published online by Nature Reviews Clinical Oncology. Essentially a road map for using immunotherapy to treat patients with melanoma, this consensus statement known as the “Society for Immunotherapy of Cancer Consensus Statement on Tumor Immunotherapy for the Treatment of Cutaneous Melanoma,” provides patients and physicians alike with expert evidence-based recommendations for the use of different immunotherapies including interferon-a2, pegylated interferon, interleukin-2 (IL-2) and ipilimumab. Recommendations for patient selection, toxicity management, clinical end points, and sequencing or combination of therapy, are also provided in this statement.

“Cancer immunotherapy is a rapidly advancing form of cancer treatment that has induced durable therapeutic responses in a subset of patients with advanced melanoma,” Michael Atkins, MD, Georgetown-Lombardi Comprehensive Cancer Center and a co-author on the paper said. “Current data suggests that cancer immunotherapy is being underutilized and many patients who might benefit from immunotherapy are not given the opportunity in the optimal setting. The goal of these guidelines is to change that and to provide a readily available and comprehensive resource about how and when to consider immunotherapy for patients with melanoma.”

Prior to the consensus statement’s publication, the lack of evidence-based guidelines in the field created obstacles and discord for practicing oncologists in the treatment of patients with melanoma. Now, this statement provides the best available evidence and consensus thinking for those interested in pursuing treatment with immunotherapy.

“The SITC consensus statement addresses the knowledge gaps and creates a standard set of guiding principles for oncologists set forth for the effective and efficient application of cancer immunotherapy for patients with melanoma,” Howard L. Kaufman, MD, FACS, Rush University Medical Center and corresponding author on the paper said. “The group of authors who developed this statement considered the strength of the evidence for key issues in the field and provided consensus recommendations in these areas; especially where data was weak or missing.”

This consensus statement was created from work done by the SITC Cancer Immunotherapy Guidelines (CIG) Task Force established in 2010 and made up of more than 30 experts in the field of melanoma. The task force utilized the 2011 Institute of Medicine’s “Standards for Developing Trustworthy Clinical Practice Guidelines” to assure a fair, transparent and balanced process for the consensus statement. However, as cancer immunotherapy continues to rapidly develop, the SITC Melanoma CIG Task Force will update the consensus statement as new findings and results from on-going clinical trials or as the approval of drugs from the FDA for the treatment of melanoma are released.

To read “The Society for Immunotherapy of Cancer Consensus Statement on Tumor Immunotherapy for the Treatment of Cutaneous Melanoma,” visit: http://www.nature.com/nrclinonc/journal/vaop/ncurrent/full/nrclinonc.2013.153.html.

For more information on the consensus statement and the Society for Immunotherapy of Cancer, visit: http://www.sitcancer.org/about-sitc/initiatives/cancer-immunotherapy-guidelines.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11066759.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Groundbreaking Nigeria summit results in major commitment to reduce child deaths
2. IU researchers interview pro-anorexic bloggers for groundbreaking new study
3. COPD Foundation and BWH announces second phase of groundbreaking COPDGene project
4. Groundbreaking clinical trial looks at fecal transplant as treatment for C. difficile
5. FEMA awards $1 Million to WPI to develop groundbreaking toxic gas sensors for firefighters
6. JTCC researchers play important role in groundbreaking study that may change transplant practices
7. MyPuress Releases Details About Groundbreaking New Product
8. Rectal microbicide research takes giant leap forward with groundbreaking educational video
9. Skin Authority Creates One-of-a-Kind Solution for the One Billion People Worldwide Who are Vitamin D Deficient -- Groundbreaking Launch of "Inside Out" System
10. Groundbreaking Training Video Prepares Surgical Team to Become Safest in the U.S.
11. Groundbreaking UK study shows key enzyme missing from aggressive form of breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2017)... ... , ... AgileMinder develops innovative products and services that bring "Care, Joy and ... Apple as a fun, free emoji sticker pack for iMessage. Use the stickers in ... coded values on The Emoji Scale. , On Apple: "The Emoji Scale by ...
(Date:1/13/2017)... ... January 13, 2017 , ... The 18th European Congress: ... hotel on March 3-4, 2017. This Congress is expertly designed to meet the ... of patients with lung cancer. , Chaired by Dr. Giorgio V. Scagliotti, Professor of ...
(Date:1/13/2017)... ... 2017 , ... With the increasing public preference for chemical-free ... organic alternatives for customers who have grown more conscious about maintaining their health ... activated charcoal products, Moody Zook Chief Executive Officer Nate Ginsburg explained their company’s ...
(Date:1/13/2017)... ... January 13, 2017 , ... People who have sensitive teeth ... pain whenever they brush their teeth. Sadly, most dental hygiene products in the market ... and teeth. For these people, continuing their daily oral care routine to keep their ...
(Date:1/13/2017)... ... January 13, 2017 , ... ... the Finnleo factory in Cokato, MN, with the official send-off from Orchestra Hall ... Maestro Osmo Vanska , Minnesota Orchestra’s Music Director, leading the official launch of ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... 2017 Eli Lilly and Company (NYSE: ... INCY ) announced today that the U.S. Food and ... the new drug application (NDA) for investigational baricitinib, a ... severe rheumatoid arthritis (RA). The NDA for baricitinib was ... The FDA extended the action date to allow time ...
(Date:1/13/2017)... -- Wichita Laser Clinic at Healthy Life ... Wichita, Kansas featuring the Astanza Revolution ... rejuvenation, getting rid of unwanted tattoos, killing toenail fungus, ... "Since being in the aesthetics industry, I have ... for laser tattoo removal and other popular cosmetic ...
(Date:1/13/2017)... , Jan. 12, 2017   JDRF ... diabetes (T1D) research, is pleased to announce that ... the Centers for Medicare & Medicaid Services (CMS) ... by the FDA for use in making diabetes ... step toward making them eligible for coverage under ...
Breaking Medicine Technology: